Standard

Harvard

APA

Vancouver

Author

BibTeX

@article{d4ceab3567a843ebb02f8e342afb0748,
title = "Vaccination against trypanosomiasis : can it be done or is the trypanosome truly the ultimate immune destroyer and escape artist?",
abstract = "To date, human African trypanosomiasis (HAT) still threatens millions of people throughout sub-Sahara Africa, and new approaches to disease prevention and treatment remain a priority. It is commonly accepted that HAT is fatal unless treatment is provided. However, despite the well-described general symptoms of disease progression during distinct stages of the infection, leading to encephalitic complications, coma and death, a substantial body of evidence has been reported suggesting that natural acquired immunity could occur. Hence, if under favorable conditions natural infections can lead to correct immune activation and immune protection against HAT, the development of an effective anti-HAT vaccine should remain a central goal in the fight against this disease. In this review, we will (1) discuss the vaccine candidates that have been proposed over the past years, (2) highlight the main obstacles that an efficient anti-trypanosomiasis vaccine needs to overcome and (3) critically reflect on the validity of the widely used murine model for HAT.",
keywords = "Human African trypanosomiasis (HAT), immune activation, immune protection",
author = "{La Greca Saint Esteven}, Florencia and Stefan Magez",
year = "2011",
month = "11",
day = "7",
language = "English",
volume = "7",
pages = "1225--1233",
journal = "Human Vaccines",
issn = "1554-8600",
publisher = "Landes Bioscience",

}

RIS

TY - JOUR

T1 - Vaccination against trypanosomiasis : can it be done or is the trypanosome truly the ultimate immune destroyer and escape artist?

AU - La Greca Saint Esteven, Florencia

AU - Magez, Stefan

PY - 2011/11/7

Y1 - 2011/11/7

N2 - To date, human African trypanosomiasis (HAT) still threatens millions of people throughout sub-Sahara Africa, and new approaches to disease prevention and treatment remain a priority. It is commonly accepted that HAT is fatal unless treatment is provided. However, despite the well-described general symptoms of disease progression during distinct stages of the infection, leading to encephalitic complications, coma and death, a substantial body of evidence has been reported suggesting that natural acquired immunity could occur. Hence, if under favorable conditions natural infections can lead to correct immune activation and immune protection against HAT, the development of an effective anti-HAT vaccine should remain a central goal in the fight against this disease. In this review, we will (1) discuss the vaccine candidates that have been proposed over the past years, (2) highlight the main obstacles that an efficient anti-trypanosomiasis vaccine needs to overcome and (3) critically reflect on the validity of the widely used murine model for HAT.

AB - To date, human African trypanosomiasis (HAT) still threatens millions of people throughout sub-Sahara Africa, and new approaches to disease prevention and treatment remain a priority. It is commonly accepted that HAT is fatal unless treatment is provided. However, despite the well-described general symptoms of disease progression during distinct stages of the infection, leading to encephalitic complications, coma and death, a substantial body of evidence has been reported suggesting that natural acquired immunity could occur. Hence, if under favorable conditions natural infections can lead to correct immune activation and immune protection against HAT, the development of an effective anti-HAT vaccine should remain a central goal in the fight against this disease. In this review, we will (1) discuss the vaccine candidates that have been proposed over the past years, (2) highlight the main obstacles that an efficient anti-trypanosomiasis vaccine needs to overcome and (3) critically reflect on the validity of the widely used murine model for HAT.

KW - Human African trypanosomiasis (HAT)

KW - immune activation

KW - immune protection

M3 - Article

VL - 7

SP - 1225

EP - 1233

JO - Human Vaccines

JF - Human Vaccines

SN - 1554-8600

ER -

ID: 2130007